Rendomab B4  (Synonyms: Rendomab-B49)

Rendomab B4 (Rendomab-B49) is a monoclonal antibody targeting ETB. Rendomab B4 preferentially binds to ETB in the active conformational state and exhibits selectivity for ETB on melanoma cells. Rendomab B4 inhibits the G protein-dependent phospholipase C (PLC) pathway, blocks ET-3-induced Gαi/o-mediated inhibition of adenylate cyclase, and does not affect the activation of the ERK1/2 pathway. Rendomab B4 is applicable to melanoma-related research^[1][2].

Human

Rendomab B4 (0.15-100 nM; overnight-1 h) binds specifically and with high affinity (apparent K_d*=0.15 nM) to human endothelin B receptor expressed on CHO-ET_B cells, and does not cross-react with rodent endothelin B receptor or human endothelin A receptor^[1].
Rendomab B4 (10 nM; overnight) does not compete with endothelin-1 or endothelin-3 for binding to human endothelin B receptor on CHO-ETB cells, indicating distinct binding sites^[1].
Rendomab B4 (1 μg/mL; 90 min) recognizes a discontinuous conformational epitope formed by two non-contiguous sequences in the N-terminal domain of human endothelin B receptor, spanning residues 28-38 and 70-77^[1].
Rendomab B4 (0.14-10 nM; overnight) binds specifically to human endothelin B receptor expressed on multiple melanoma cell lines, with the highest affinity for UACC-257 cells (apparent K_d=0.14 nM), and does not bind to endothelin B receptor on non-cancerous HEK293T or HUVEC cells^[1].
Rendomab B4 (150 nM; 2 h 30 min) potently inhibits endothelin-1 and endothelin-3-induced phospholipase C activation in UACC-257 melanoma cells, reducing activity by approximately 75%^[1].
Rendomab B4 (150 nM; 2 h 5 min) does not inhibit endothelin-1 or endothelin-3-induced ERK1/2 phosphorylation in UACC-257 melanoma cells, demonstrating a biased inhibitory effect on endothelin B receptor signaling pathways^[1].
Rendomab B4 (150 nM; 22 h) completely inhibits endothelin-1-induced migration of UACC-257 melanoma cells, without affecting baseline cell migration^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Rendomab-B49 (as chimeric xiRB49) (4 mg/kg; i.p.; 2 doses) does not inhibit melanoma xenograft progression in athymic nude mice, with no observed treatment-related toxicity^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1910  [NCBI]

P24530

EDNRB/Endothelin R

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

[Rendomab B4]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Borrull A, et al. Rendomab B4, a monoclonal antibody that discriminates the human endothelin B receptor of melanoma cells and inhibits their migration. MAbs. 2016;8(7):1371-1385.  [Content Brief]

  [2]. Herbet A, et al. Targeting the activated allosteric conformation of the endothelin receptor B in melanoma with an antibody-drug conjugate: mechanisms and therapeutic efficacy. BJC Rep. 2025;3(1):3. Published 2025 Jan 20.  [Content Brief]